Amid a sweeping tightening of securities regulatory policies since late 2023, there has been a dearth of initial public offerings for bioventures in the Chinese mainland.
China Biotech IPO Drought Lingers But HK Sees First Of 2024
Biotech IPOs on the Chinese mainland have dried up since June 2023 due to regulatory tightening, but Hong Kong is still open to listings of pre-revenue ventures and has seen its first offering of this year.
